Cargando…
Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study
INTRODUCTION: In COVID 19, an aggressive inflammatory response called cytokine release storm has been described. It is mainly mediated by the activation of Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), mainly observed in critically ill patients. Among the multiple treatments proposed...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asociación Colombiana de Medicina Crítica y Cuidado lntensivo. Published by Elsevier España, S.L.U.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671622/ http://dx.doi.org/10.1016/j.acci.2022.10.004 |
_version_ | 1784832589787299840 |
---|---|
author | Anci, Cynthia Solavallone, Vanina Cardone, Romina Orlando, Juan Manuel |
author_facet | Anci, Cynthia Solavallone, Vanina Cardone, Romina Orlando, Juan Manuel |
author_sort | Anci, Cynthia |
collection | PubMed |
description | INTRODUCTION: In COVID 19, an aggressive inflammatory response called cytokine release storm has been described. It is mainly mediated by the activation of Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), mainly observed in critically ill patients. Among the multiple treatments proposed throughout these two years of pandemic, we highlight the use of Tocilizumab (TCZ). OBJECTIVES: To evaluate in-hospital mortality, transfer to critical care unit (CCU), invasive mechanical ventilation requirement (IMV), and hospital stay in patients treated with TCZ versus conventional treatments (CT). METHODS: Retrospective, descriptive, and analytical cohort study. Hospitalized patients, May to July 2021. Branches: treated with TCZ versus CT. Statistical analysis: Epi Info 7.2. RESULTS: Ninety patients, 51 TCZ branch and 39 CT branch. Age 48.2 years (± 11.7), males 74 (82.2%). Comorbidities 66 (73.3%): High blood pressure (HBP) 32 (35.6%), Diabetes mellitus 13 (14.4%), BMI > 30, 51 (56.7%). Medical Clinic Admission (MC) 85 (94.4%). Days post-symptom onset 7.9 (± 2.6). Severity of COVID 19: severe 61 (67.8%), critical 26 (28.9%). CCU admission 26 (29.9%). IMV 16 (17.8%). Deaths 7 (7.9%). Hospital stay 12.9 (± 6.6) days. Comparative analysis TCZ versus CT: MC admission 50 (98%) versus 35 (89.7%) p .08. CCU admission 12 (23.5%) versus 14 (38.9%) p .1. IMV 4 (7.8%) versus 12 (30.8%) p .005. Death 1 (2.0%) versus 6 (15.8%) p .02. Mortality in univariate analysis (p < .05): APACHE II, BMI > 30, TCZ, IMV, and CCU admission. TCZ was a protective factor against RR of death .86 (.74–.99). The IMV requirement was a RR factor for death 2.0 (1.23–3.42). Cox logistic regression, independent survival factors: use of TCZ, absence of obesity, and no IMV, p .0000. CONCLUSIONS: IMV was found to be a risk factor for mortality. TCZ did not show a decrease in CCU requirement, but it did prove to be a protective factor against mortality. However, this is a non-randomized study so it should be interpreted with caution. |
format | Online Article Text |
id | pubmed-9671622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Asociación Colombiana de Medicina Crítica y Cuidado lntensivo. Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96716222022-11-18 Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study Anci, Cynthia Solavallone, Vanina Cardone, Romina Orlando, Juan Manuel Acta Colombiana de Cuidado Intensivo Original Article INTRODUCTION: In COVID 19, an aggressive inflammatory response called cytokine release storm has been described. It is mainly mediated by the activation of Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), mainly observed in critically ill patients. Among the multiple treatments proposed throughout these two years of pandemic, we highlight the use of Tocilizumab (TCZ). OBJECTIVES: To evaluate in-hospital mortality, transfer to critical care unit (CCU), invasive mechanical ventilation requirement (IMV), and hospital stay in patients treated with TCZ versus conventional treatments (CT). METHODS: Retrospective, descriptive, and analytical cohort study. Hospitalized patients, May to July 2021. Branches: treated with TCZ versus CT. Statistical analysis: Epi Info 7.2. RESULTS: Ninety patients, 51 TCZ branch and 39 CT branch. Age 48.2 years (± 11.7), males 74 (82.2%). Comorbidities 66 (73.3%): High blood pressure (HBP) 32 (35.6%), Diabetes mellitus 13 (14.4%), BMI > 30, 51 (56.7%). Medical Clinic Admission (MC) 85 (94.4%). Days post-symptom onset 7.9 (± 2.6). Severity of COVID 19: severe 61 (67.8%), critical 26 (28.9%). CCU admission 26 (29.9%). IMV 16 (17.8%). Deaths 7 (7.9%). Hospital stay 12.9 (± 6.6) days. Comparative analysis TCZ versus CT: MC admission 50 (98%) versus 35 (89.7%) p .08. CCU admission 12 (23.5%) versus 14 (38.9%) p .1. IMV 4 (7.8%) versus 12 (30.8%) p .005. Death 1 (2.0%) versus 6 (15.8%) p .02. Mortality in univariate analysis (p < .05): APACHE II, BMI > 30, TCZ, IMV, and CCU admission. TCZ was a protective factor against RR of death .86 (.74–.99). The IMV requirement was a RR factor for death 2.0 (1.23–3.42). Cox logistic regression, independent survival factors: use of TCZ, absence of obesity, and no IMV, p .0000. CONCLUSIONS: IMV was found to be a risk factor for mortality. TCZ did not show a decrease in CCU requirement, but it did prove to be a protective factor against mortality. However, this is a non-randomized study so it should be interpreted with caution. Asociación Colombiana de Medicina Crítica y Cuidado lntensivo. Published by Elsevier España, S.L.U. 2023 2022-11-17 /pmc/articles/PMC9671622/ http://dx.doi.org/10.1016/j.acci.2022.10.004 Text en © 2022 Asociación Colombiana de Medicina Crítica y Cuidado lntensivo. Published by Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Anci, Cynthia Solavallone, Vanina Cardone, Romina Orlando, Juan Manuel Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study |
title | Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study |
title_full | Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study |
title_fullStr | Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study |
title_full_unstemmed | Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study |
title_short | Use of tocilizumab in COVID-19 pneumonia hospitalized patients. Cohort study |
title_sort | use of tocilizumab in covid-19 pneumonia hospitalized patients. cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671622/ http://dx.doi.org/10.1016/j.acci.2022.10.004 |
work_keys_str_mv | AT ancicynthia useoftocilizumabincovid19pneumoniahospitalizedpatientscohortstudy AT solavallonevanina useoftocilizumabincovid19pneumoniahospitalizedpatientscohortstudy AT cardoneromina useoftocilizumabincovid19pneumoniahospitalizedpatientscohortstudy AT orlandojuanmanuel useoftocilizumabincovid19pneumoniahospitalizedpatientscohortstudy |